We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+46.74%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.57B
AUM Growth
+$1.21B
Cap. Flow
-$9.19M
Cap. Flow %
-0.26%
Top 10 Hldgs %
45.04%
Holding
142
New
39
Increased
22
Reduced
59
Closed
10

Top Buys

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$68.1M
2
GBIO
Generation Bio
GBIO
+$62.7M
3
RPRX icon
Royalty Pharma
RPRX
+$37.1M
4
ONC
BeOne Medicines Ltd
ONC
+$32.6M
5
NG icon
NovaGold Resources
NG
+$26.3M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$137M
2
AVTR icon
Avantor
AVTR
+$40.7M
3
PYPL icon
PayPal
PYPL
+$33.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$27M
5
Z icon
Zillow
Z
+$20.7M

Sector Composition

Rank Sector Weight
1 Healthcare 62.42%
2 Miscellaneous 17.82%
3 Consumer Discretionary 13.38%
4 Technology 3.16%
5 Financials 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRVL
101
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$5.51M 0.15%
370,000
+170,000
+85% +$2.62M
TCRR
102
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$5.38M 0.15%
350,000
-50,000
-13% -$577K
SLDB icon
103
Solid Biosciences
SLDB
$897M
$5.27M 0.15%
120,000
– –
SYRS
104
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.22M 0.15%
49,000
-1,614
-3% -$145K
ORIC icon
105
Oric Pharmaceuticals
ORIC
$1.28B
$5.06M 0.14%
+150,000
New +$4.79M
NTLA icon
106
Intellia Therapeutics
NTLA
$1.59B
$5.02M 0.14%
+239,000
New +$4.06M
AXLA
107
DELISTED
Axcella Health Inc. Common Stock
AXLA
$4.98M 0.14%
36,000
+12,000
+50% +$1.47M
RNAM
108
DELISTED
Avidity Biosciences
RNAM
$4.95M 0.14%
+175,000
New +$5.05M
ALEC icon
109
Alector
ALEC
$228M
$4.89M 0.14%
200,000
-50,000
-20% -$1.38M
ZNTL icon
110
Zentalis Pharmaceuticals
ZNTL
$296M
$4.42M 0.12%
+92,000
New +$3.53M
YI
111
111 Inc
YI
$30.7M
$4.13M 0.12%
65,000
– –
PRTA icon
112
Prothena Corp
PRTA
$428M
$3.87M 0.11%
370,000
+70,000
+23% +$778K
KLDO
113
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$3.72M 0.1%
500,500
– –
IDYA icon
114
IDEAYA Biosciences
IDYA
$3.63B
$3.4M 0.1%
+239,304
New +$1.89M
DNTH icon
115
Dianthus Therapeutics
DNTH
$5.86B
$3.38M 0.09%
+28,125
New +$3.96M
CLVS
116
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$3.38M 0.09%
500,000
– –
EVLO
117
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$3.27M 0.09%
+33,333
New +$2.92M
LITS
118
Lite Strategy Inc
LITS
$37.1M
$2.95M 0.08%
+35,700
New +$2.16M
NERV icon
119
Minerva Neurosciences
NERV
$183M
$2.89M 0.08%
100,000
-25,000
-20% -$1.47M
CYRX icon
120
CryoPort
CYRX
$826M
$2.69M 0.08%
+89,000
New +$1.98M
PTGX icon
121
Protagonist Therapeutics
PTGX
$9.28B
$2.47M 0.07%
+140,000
New +$1.76M
ORTX
122
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$2.22M 0.06%
37,000
-3,000
-8% -$275K
KDNY
123
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.19M 0.06%
190,000
-10,000
-5% -$138K
ACET icon
124
Adicet Bio
ACET
$79.7M
$2.05M 0.06%
+8,509
New +$1.67M
XLE icon
125
CALL
State Street Energy Select Sector SPDR ETF
XLE
$43.3B
$1.89M 0.05%
+100,000
New +$1.86M
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2020 Portfolio in Review

As of Q2 2020, Artal Group held 142 positions worth $3.57B, up 51% from $2.37B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group's Q2 2020 filing shows 39 new, 22 increased, 59 reduced and 10 closed positions. Its largest new stake was GDS Holdings: 1,100,000 shares worth $87.6M. The largest sale was Moderna, an estimated $137M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 69% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Artal Group's largest Q2 2020 buy was GDS Holdings: 1,100,000 shares worth $87.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q2 2020, an estimated $32.6M increase.
  • Artal Group's biggest Q2 2020 reduction was Moderna, cutting an estimated $137M.
  • Artal Group fully exited Arrowhead Research in Q2 2020, selling an estimated $17.3M.
  • Artal Group's ten largest holdings make up 45% of its $3.57B portfolio in Q2 2020.
  • Artal Group opened 39 new positions and closed 10 in Q2 2020.
  • Artal Group's portfolio value rose 51% quarter-over-quarter to $3.57B.

Based on Artal Group's 13F filing for Q2 2020, filed 14 Aug 2020.